Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Tuberculosis

ClinicalTrials.gov lists 1,529 trials for Tuberculosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 84.

MeSH D014376 Infections C01 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 179 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 209 Phase 2/3 Phase 2/3 36 Phase 3 Phase 3 130 Phase 4 Phase 4 100 Not applicable Not applicable 384 Observational Observational 459 Phase 1 Phase 1 179 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 209 Phase 2/3 Phase 2/3 36 Phase 3 Phase 3 130 Phase 4 Phase 4 100 Not applicable Not applicable 384 Observational Observational 459

Trials per phase

1 more section with rows

1,140 of the 1,529 trials are tagged with Tuberculosis itself; the rest are tagged with a narrower condition beneath it.

Get the Tuberculosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Tuberculosis trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 99

1990: 1 trials (Phase 2 1) 1992: 1 trials (Observational 1) 1994: 5 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 2 1) 1995: 8 trials (Observational 6, Not applicable 1, Phase 3 1) 1996: 1 trials (Phase 4 1) 1998: 2 trials (Phase 3 1, Phase 2 1) 1999: 4 trials (Not applicable 1, Phase 2/3 1, Phase 2 2) 2000: 7 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 2) 2001: 5 trials (Phase 4 1, Phase 3 3, Phase 2/3 1) 2002: 9 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 2, Phase 1 1) 2003: 11 trials (Observational 1, Not applicable 3, Phase 4 2, Phase 3 1, Phase 2 1, Phase 1 3) 2004: 22 trials (Observational 5, Not applicable 3, Phase 4 3, Phase 3 3, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 3) 2005: 38 trials (Observational 17, Not applicable 5, Phase 4 3, Phase 3 4, Phase 2 5, Phase 1 4) 2006: 29 trials (Observational 8, Not applicable 1, Phase 4 3, Phase 3 5, Phase 2 6, Phase 1/2 2, Phase 1 4) 2007: 42 trials (Observational 14, Not applicable 8, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 9) 2008: 56 trials (Observational 10, Not applicable 8, Phase 4 6, Phase 3 10, Phase 2 10, Phase 1 12) 2009: 64 trials (Observational 17, Not applicable 19, Phase 4 3, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 10) 2010: 61 trials (Observational 18, Not applicable 6, Phase 4 7, Phase 3 4, Phase 2 13, Phase 1/2 1, Phase 1 12) 2011: 51 trials (Observational 14, Not applicable 10, Phase 4 4, Phase 3 5, Phase 2 12, Phase 1 6) 2012: 64 trials (Observational 23, Not applicable 13, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 8, Phase 1 8) 2013: 53 trials (Observational 12, Not applicable 12, Phase 4 3, Phase 3 3, Phase 2/3 2, Phase 2 10, Phase 1/2 3, Phase 1 8) 2014: 60 trials (Observational 13, Not applicable 15, Phase 4 6, Phase 3 6, Phase 2/3 3, Phase 2 12, Phase 1/2 2, Phase 1 3) 2015: 74 trials (Observational 19, Not applicable 22, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 12) 2016: 64 trials (Observational 18, Not applicable 15, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 11, Phase 1 9) 2017: 70 trials (Observational 21, Not applicable 19, Phase 4 5, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1/2 3, Phase 1 10) 2018: 59 trials (Observational 21, Not applicable 19, Phase 4 2, Phase 3 1, Phase 2/3 2, Phase 2 4, Phase 1/2 2, Phase 1 8) 2019: 98 trials (Observational 36, Not applicable 28, Phase 4 2, Phase 3 6, Phase 2/3 3, Phase 2 11, Phase 1/2 5, Phase 1 7) 2020: 73 trials (Observational 20, Not applicable 21, Phase 4 5, Phase 3 6, Phase 2/3 4, Phase 2 8, Phase 1 9) 2021: 99 trials (Observational 38, Not applicable 31, Phase 4 6, Phase 3 3, Phase 2/3 2, Phase 2 14, Phase 1 5) 2022: 88 trials (Observational 30, Not applicable 22, Phase 4 6, Phase 3 8, Phase 2/3 3, Phase 2 11, Phase 1/2 2, Phase 1 6) 2023: 78 trials (Observational 20, Not applicable 23, Phase 4 4, Phase 3 5, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 8) 2024: 77 trials (Observational 30, Not applicable 21, Phase 4 4, Phase 3 8, Phase 2 4, Phase 1/2 3, Phase 1 7) 2025: 60 trials (Observational 22, Not applicable 13, Phase 4 1, Phase 3 8, Phase 2/3 2, Phase 2 8, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 76
2025 60
2024 77
2023 78
2022 88
2021 99
2020 73
2019 98
2018 59
2017 70

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 89 trials starting in 2026 and about 68 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 106 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 943 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Tuberculosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 179
Phase 1/2 31
Phase 2 209
Phase 2/3 36
Phase 3 130
Phase 4 100
Not applicable 384
Observational 459
Expanded access 1

How many Tuberculosis trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 72
Recruiting 132
Enrolling by invitation 9
Active, not recruiting 45
Completed 923

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Tuberculosis trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 84
Centers for Disease Control and Prevention 28
GlaxoSmithKline 19
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 17

Which drugs are being tested for Tuberculosis? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Bedaquiline 56
Delamanid 26
MVA85A 22
Rifabutin 18
Clofazimine 18

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Isoniazida 104
Rifampicin 82
Pyrazinamide Oral Product 60
C: moxifloxacin 43
Ethambutol Oral Product 42

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Tuberculosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 375 22
Gastroenteritis 277 20
Pneumonia 204 32
Malaria 102 7
Dyspnea or Respiratory Distress 71 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Tuberculosis? (1,391)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial. The lancet. HIV 2026 Yes
A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries. The Journal of infectious diseases 2025 Yes
Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). Emerging microbes & infections 2025 Yes
Low-complexity automated nucleic acid amplification tests for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents. The Cochrane database of systematic reviews 2025 Yes
Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluation. EBioMedicine 2025 Yes

Showing 5 of 1,391 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (120)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Tuberculosis Annual incidence 1-5 / 10 000 United Kingdom GB Unspecified
Tuberculosis Annual incidence 1-5 / 10 000 United Kingdom GB Exact
Tuberculosis Annual incidence 1-5 / 10 000 United Kingdom GB Exact
Tuberculosis Annual incidence 1-9 / 100 000 United States US Exact
Tuberculosis Annual incidence 1-9 / 100 000 United States US Unspecified

Showing 5 of 120 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Tuberculosis 3389 Exact Orphadata Science knowledge files, Product 1
Tuberculosis 3389 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages